Alzamend Neuro Stock Analysis

Alzamend Stock Analysis Notes

The company recorded a loss per share of 142.87. Alzamend Neuro had not issued any dividends in recent years. The entity had 1:10 split on the 16th of July 2024. Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. Alzamend Neuro operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. For more info on Alzamend Neuro please contact Stephan Jackman at 844 722 6333 or go to https://www.alzamend.com.

Alzamend Neuro Investment Alerts

Alzamend Neuro Upcoming and Recent Events

Alzamend Largest EPS Surprises

View All Earnings Estimates

Alzamend Stock Institutional Investors

Note, although Alzamend Neuro's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Alzamend Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.86 M.

Alzamend Profitablity

Management Efficiency

Alzamend Neuro has return on total asset (ROA) of (2.1447) % which means that it has lost $2.1447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (44.0831) %, meaning that it created substantial loss on money invested by shareholders. Alzamend Neuro's management efficiency ratios could be used to measure how well Alzamend Neuro manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of November 2024, Return On Tangible Assets is likely to grow to -14.96. In addition to that, Return On Capital Employed is likely to drop to 3.64. As of the 23rd of November 2024, Debt To Assets is likely to grow to 0.95, while Net Tangible Assets are likely to drop about 3.3 M.

Technical Drivers

As of the 23rd of November, Alzamend Neuro shows the Mean Deviation of 3.22, risk adjusted performance of (0.25), and Standard Deviation of 4.06. Alzamend Neuro technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Alzamend Neuro Price Movement Analysis

Alzamend Neuro Insider Trading Activities

Alzamend Neuro Outstanding Bonds

Alzamend Neuro Predictive Daily Indicators

Alzamend Neuro Forecast Models

Alzamend Neuro's time-series forecasting models are one of many Alzamend Neuro's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Alzamend Neuro's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Alzamend Neuro prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Alzamend shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Alzamend Neuro. By using and applying Alzamend Stock analysis, traders can create a robust methodology for identifying Alzamend entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Alzamend analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Alzamend analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Alzamend Neuro stock analysis indicators help investors evaluate how Alzamend Neuro stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Alzamend Neuro shares will generate the highest return on investment. By understating and applying Alzamend Neuro stock analysis, traders can identify Alzamend Neuro position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.